Difference between revisions of "Part:BBa K3582005"

Revision as of 10:54, 19 October 2020

Inhibitory Sequence 1 Grafted In Cyclotide Kalata B1

The biobrick is believed to synthesize the readily deliverable cyclotide drug that could inhibit the 5LGD interaction between the host protein (CD36) and the parasite protein (CIDRa domain of PfEMP1). Different components involved in this biobrick are described below:

1]BBa_K3582020: C intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
2]BBa_K2333015: Bsa 1 Reversed recognition site
3]The cyclotide precursor(scar): The gene coding for the 29 amino-acids of cyclotide Kalata B1 are inserted between the C Intein and the N intein so that it gets circularized after translation.
4]Strep II tag: This tag is inserted in loop 3 of the cyclotide construct to reduce the haemolytic activity of the cyclotide and ease of purification.
5]BBa_k3582012: Inhibitory peptide sequence 1 (IS1) grafted in loop 6 of the cyclotide structure to avoid the host-parasite protein interaction. This mutant sequence has a higher affinity for interaction as compared to wild type.
6]BBa_K3582021: Bsa 1 recognition site
7]BBa_K3582022: N intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.

The final translated protein product obtained using this biobrick is believed to act as a drug for preventing the CD36-PfEMP1 interaction.

Sequence and Features

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
INCOMPATIBLE WITH RFC[25]
Illegal AgeI site found at 112
1000
INCOMPATIBLE WITH RFC[1000]
Illegal BsaI site found at 143
Illegal BsaI.rc site found at 109

@@ Line 4: / Line 4: @@
 The biobrick is believed to synthesize the readily deliverable cyclotide drug that could inhibit the 5LGD interaction between the host protein (CD36) and the parasite protein (CIDRa domain of PfEMP1). Different components involved in this biobrick are described below:
-]BBa_k1362401: C intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
+*1]BBa_K3582020: C intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
-]BBa_k1362400: N intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
+*2]BBa_K2333015: Bsa 1 Reversed recognition site
-]The cyclotide precursor: The gene coding for the 29 amino-acids of cyclotide Kalata B1 are inserted between the C Intein and the N intein so that it gets circularized after translation.
+*3]The cyclotide precursor(scar): The gene coding for the 29 amino-acids of cyclotide Kalata B1 are inserted between the C Intein and the N intein so that it gets circularized after translation.
-]Strep II tag: This tag is inserted in loop 3 of the cyclotide construct to reduce the haemolytic activity of the cyclotide and ease of purification.
+*4]Strep II tag: This tag is inserted in loop 3 of the cyclotide construct to reduce the haemolytic activity of the cyclotide and ease of purification.
-]BBa_k3582002: Inhibitory peptide sequence 1 (IS1) grafted in loop 6 of the cyclotide structure to avoid the host-parasite protein interaction. This mutant sequence has a higher affinity for interaction as compared to wild type.
+*5]BBa_k3582012: Inhibitory peptide sequence 1 (IS1) grafted in loop 6 of the cyclotide structure to avoid the host-parasite protein interaction. This mutant sequence has a higher affinity for interaction as compared to wild type.
+*6]BBa_K3582021: Bsa 1 recognition site
+*7]BBa_K3582022: N intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
 The final translated protein product obtained using this biobrick is believed to act as a drug for preventing the CD36-PfEMP1 interaction.